CollPlant Biotechnologies Ltd. (CLGN), Monday announced encouraging results from a head-to-head comparative study of its rhCollagen-based bioink, Collink.3D, and Matrigel, developed and marketed by Corning.
Conducted by Levenberg Lab at Technion - Israel Institute of Technology, the study demonstrated Collink.3D's enhanced mechanical strength, elasticity, and stability, suggesting that it may serve as a next-generation, animal-free extracellular matrix.
CEO Yehiel Tal noted, "The results reinforce Collink.3D as a biologically supportive and durable bioink that promotes cell organization and tissue development while maintaining structural integrity over time."
In the pre-market hours, CLGN is trading at $2.39, up 3.02 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.